Get started
Author

Marwan N. Sabbagh

Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit
2023 · Rita Sattler, Bryan J. Traynor, et al. · Neurology and Therapy · 32
PDF
Amyloid-Directed Antibodies: Past, Present, and Future
2024 · Keith Noorda, Kevin Noorda, et al. · Journal of Alzheimer s Disease · 9
PDF
Active immunization targeting amyloid β for the treatment of Alzheimer’s disease
2025 · Olivia Triplett, Nicole Varda, et al. · Neurodegenerative Diseases · 5
PDF
Informant-Based Questionnaires in the Diagnostic Pathway for Screening of Cognitive Impairment
2025 · Abarajithan Chandrasekaran, Michael Malek-Ahmadi, et al. · Neurology and Therapy · 3
PDF
Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?
2025 · Katia Azarfar, Boris Decourt, et al. · Expert Review of Neurotherapeutics · 3
PDF
Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results
2025 · Marwan N. Sabbagh, Sharon Cohen, et al. · Alzheimer s & Dementia · 2
PDF
Precision Medicine in Alzheimer’s Disease (AD): Observed Efficacy Treatment Effects from Blarcamesine Clinical AD Trials
2025 · Marwan N. Sabbagh, Audrey Gabelle, et al. · Alzheimer s & Dementia · 2
PDF
Real‐world utilization of diagnostic tests for mild cognitive impairment, Alzheimer’s disease, and other dementias in Medicare fee‐for‐service beneficiaries
2024 · Jessie T. Yan, Allison Dillon, et al. · Alzheimer s & Dementia · 2
PDF
Real‐World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic Therapy
2025 · Marwan N. Sabbagh, David C Weisman, et al. · Alzheimer s & Dementia · 1
PDF
Phase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease Patients
2025 · Marwan N. Sabbagh, Stephen Macfarlane, et al. · Alzheimer s & Dementia · 1
PDF
Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease
2025 · Ralph Kern, Benjamin Haaland, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 1
PDF
Amyloid-Directed Antibodies: Past, Present, and Future
2024 · Keith Noorda, Kevin Noorda, et al. · Advances in Alzheimer's disease · 1
Editorial: Biofluid biomarkers for the diagnosis of neurodegenerative diseases: current status
2026 · Boris Decourt, Michelle M. Mielke, et al. · Frontiers in Neuroscience
PDF
Autophagy in Alzheimer’s Disease: Mechanisms, Clinical Trials, and Horizons
2026 · Tshibambe N. Tshimbombu, Kyle E. Thurmann, et al. · Neurodegenerative Diseases
PDF
Analysis of second-generation epigenetic clocks reveals further associations between disproportionate biological ageing and hippocampal volume
2026 · Lidija Milicic, Michael Vacher, et al. · GeroScience
PDF
Delirium and dementia in the ICU - A neurocritical care perspective
2026 · Fiona Lynch, C. Patrick Crooks, et al. · Expert Review of Neurotherapeutics
Blood‐Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer’s Disease in the United States
2025 · Cara Leahy, Michael Henry Rosenbloom, et al. · Alzheimer s & Dementia
PDF
Real‐World Use of Lecanemab With Consideration of Race, Ethnicity, and Geographical Diversity
2025 · Jose Soria‐Lopez, Michael Henry Rosenbloom, et al. · Alzheimer s & Dementia
PDF
Safety and ARIA Results of the Oral Anti‐Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD
2025 · Patrick Kesslak, Susan Abushakra, et al. · Alzheimer s & Dementia
PDF
Real‐World Use of Lecanemab in Patients With Early Alzheimer’s Disease in the United States: a Case Series Review
2025 · David C Weisman, Michael Henry Rosenbloom, et al. · Alzheimer s & Dementia
PDF
Real‐World Insights on the Lecanemab Patient Pathway in Early Alzheimer’s Disease in the United States
2025 · Michael Henry Rosenbloom, Marwan N. Sabbagh, et al. · Alzheimer s & Dementia
PDF
Efficacy and Safety of Oral Valiltramiprosate in APOE4/4 Homozygotes with Early AD: Topline Results from the APOLLOE4 Phase 3 Trial
2025 · Aidan Power, Susan Abushakra, et al. · Alzheimer s & Dementia
PDF
Physician Satisfaction With Lecanemab in Early Alzheimer's Disease: Real‐World Insights From Prescribers in the United States
2025 · Gregory Cooper, Michael Henry Rosenbloom, et al. · Alzheimer s & Dementia
PDF
Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre‐Specified MCI Group: Subgroup Analysis from the 78‐Week APOLLOE4 Phase 3 Trial in APOE4/4 Homozygotes
2025 · Susan Abushakra, P. Murali Doraiswamy, et al. · Alzheimer s & Dementia
PDF
Valiltramiprosate Effects on Microstructural Integrity of Grey and White Matter in APOE4/4 Homozygotes with Early AD and their Correlations to Clinical Outcomes: MRI Mean Diffusivity Results from the 78‐Week APOLLOE4 Phase 3 Trial
2025 · Earvin Liang, Susan Abushakra, et al. · Alzheimer s & Dementia
PDF
Works count: 32
Citation count: 62
H-index: 3
I10-index: 1
Year
Topic
Type